Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fermented germinated brown rice
- Development stage
- Preclinical
- Lead developer
- Japanese company
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fermented germinated brown rice (FGBR) is a functional food and dietary supplement candidate produced by fermenting germinated brown rice (GBR) with probiotic bacteria, specifically *Lactobacillus acidophilus*. It is being investigated for its potential chemopreventive effects against colorectal cancer (CRC). The fermentation process is thought to enhance the bioactive properties of GBR, leading to increased anti-inflammatory and pro-apoptotic activities. In preclinical models of colorectal carcinogenesis, FGBR has demonstrated the ability to reduce the formation of preneoplastic aberrant crypt foci (ACF) and sialomucin-producing ACF (SIM-ACF). Its mechanism of action involves the suppression of pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β, and the modulation of apoptotic pathways by upregulating Bax and cleaved caspase-3 while downregulating the anti-apoptotic protein Bcl-2.
- Other names
- FGBRgerminated brown rice fermented by Lactobacillus acidophilus
02
Targets
BAX (Apoptosis regulator BAX)CASP3 (Caspase-3)IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on fermented germinated brown rice.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fermented germinated brown rice.